A group of British patients has begun to receive the vaccine that the Moderna company has designed against cancer. This is a messenger RNA immunization inspired by that of covid-19 .
And, as detailed by the British media The Independentmore patients are being recruited from other parts of the world, such as Spain, to continue with the trial, called Mobilize.
The objective pursued with this test, which is led by Imperial College London and the Imperial College Healthcare NHS Trust, is none other than to measure the level of both potential and safety of the inoculation to treat lung cancer, melanoma and other types of “solid tumor” cancersdetails the London institution.
The vaccine in question has been designed using messenger RNAwhich implies that its function is to help the human body recognize cells that are cancerous and fight them.
During the trials, according to the aforementioned British newspaper, only the vaccine will be administered. Although it is also combined with a drug that serves as an immunotherapy treatmentpembrolizumab.
From more parts of the world
The Mobilize trial is recruiting more patients from other countries around the world, such as Spain, Australia and the United States, according to The Independentwhich has reported that there are experts who trust that these advances may be effective in combating different types of cancer.
This was explained by the head of development, therapeutics and oncology at Moderna, Dr. Kyle Holen, in statements collected by the aforementioned media. “We are currently studying both melanoma patients and lung cancer patients, but we believe there is an opportunity for this vaccine in the Mobilize trial to treat many other cancers,” he said.
For his part, consultant medical oncologist at Imperial College Healthcare NHS Trust, Dr. David Pinato, maintains that “the appeal” of these vaccines is that “they can be made much more specific: basically written instructions can be given to the immune system.” . “It’s almost like a tumor cell identification kit, which is more precise”he added.